<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="131176">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01976377</url>
  </required_header>
  <id_info>
    <org_study_id>201307074RIND</org_study_id>
    <nct_id>NCT01976377</nct_id>
  </id_info>
  <brief_title>Mucin Glycosylating Enzymes in Head and Neck Cancers</brief_title>
  <official_title>Expression of Mucin Glycosylating Enzymes in Head and Neck Cancers and Its Correlation With Clinico-pathological Parameters.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <oversight_info>
    <authority>Taiwan: Department of Health</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Head and neck squamous cell carcinoma(HNSCC) is the fourth common malignancy in Taiwan. It
      accounts for 5.8% of all cancers and causes 2,463 deaths per year. Aberrant glycosylation is
      the hallmark of most human cancers, including HNSCC, and affects many cellular properties.
      This study is aimed at exploring the role of mucin glycosylating enzymes in HNSCC.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Glycosylation is the most common post-translational modification of proteins. Aberrant
      glycosylation is the hallmark of most human cancers and affect many cellular properties,
      including cell proliferation, apoptosis, differentiation, transformation, migration and
      immune response.

      Though widely explored in various human cancers, the role of mucin glycosylating enzymes in
      HNSCC has not been elucidated. Our aims is to analyze the expression patterns of mucin
      glycosylating enzymes in HNSCC tissues. Furthermore, we will correlate the expression levels
      of mucin glycosylating enzymes with clinical characteristics of HNSCC patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">October 2016</completion_date>
  <primary_completion_date type="Anticipated">October 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case Control, Time Perspective: Retrospective</study_design>
  <primary_outcome>
    <measure>Measure the expression of mucin glycosylating in head and neck cancer</measure>
    <time_frame>1~5 years after patient received surgery</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Mucin Glycosylating Enzyme, HNSCC</condition>
  <arm_group>
    <arm_group_label>Stage I, II, III, IV HNSCC</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Head and neck cancer patients receiving operation in National Taiwan University Hospital
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Head and neck cancer patients receiving operation in National Taiwan University
             Hospital

        Exclusion Criteria:

          -  Recurrence or non-operable patients
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pei-Jen Lou, M.D, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Taiwan University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pei-Jen Lou, M.D, Ph.D</last_name>
    <phone>886-972651527</phone>
    <email>pjlou@ntu.edu.tw</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mei-Chun Lin</last_name>
    <phone>886-978261268</phone>
    <email>b91401051@ntu.edu.tw</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>National Taiwan University</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pei-Jen Lou, MD, PhD</last_name>
      <phone>886-972651527</phone>
      <email>pjlou@ntu.edu.tw</email>
    </contact>
    <contact_backup>
      <last_name>Mei-Chun Lin</last_name>
      <phone>886-978261268</phone>
      <email>b91401051@ntu.edu.tw</email>
    </contact_backup>
    <investigator>
      <last_name>Pei-Jen Lou, M.D, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 29, 2013</lastchanged_date>
  <firstreceived_date>October 22, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
